Azipramine
Azipramine is a tricyclic antidepressant (TCA) that was developed in the 1960s but was never marketed. It is structurally related to other tricyclic antidepressants such as imipramine and desipramine.
Pharmacology[edit]
Azipramine acts primarily as a serotonin-norepinephrine reuptake inhibitor (SNRI), increasing the levels of serotonin and norepinephrine in the brain by inhibiting their reuptake into neurons. This results in an increase in the concentration of these neurotransmitters in the synaptic cleft, leading to increased neurotransmission.
Azipramine also has significant anticholinergic effects, which can lead to side effects such as dry mouth, constipation, urinary retention, and blurred vision. It also has antihistamine effects, which can lead to sedation.
Clinical Use[edit]
Despite its development, Azipramine was never marketed for use in any country. It is not currently approved for any medical uses. However, it has been studied in clinical trials for the treatment of various psychiatric disorders, including major depressive disorder and anxiety disorders.
Side Effects[edit]
The side effects of Azipramine are similar to those of other tricyclic antidepressants. These can include dry mouth, constipation, urinary retention, blurred vision, and sedation. More serious side effects can include cardiac arrhythmias, orthostatic hypotension, and seizures.
See Also[edit]
